Janus Henderson to Report Fourth Quarter and Full-Year 2023 Results
LONDON–(BUSINESS WIRE)–Janus Henderson Group plc (NYSE: JHG) will announce its fourth quarter and full-year 2023 results on Thursday, February 1, 2024,... Read more.
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
First of its kind research investigated the impact of the changing weight-loss market on the Allurion Program Research included 172 healthcare professionals (HCPs)... Read more.
Global Content Management Systems (CMS) Digital Trends Report 2023 Featuring Adobe Commerce, Amazon, Contentful, Storyblok, and WordPress – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Digital Trends for the CMS: Market Insights for Content Leaders” report has been added to ResearchAndMarkets.com’s... Read more.
Byline Bancorp, Inc. to Announce Fourth Quarter 2023 Financial Results on Thursday, January 25
Conference call and webcast to be held on Friday, January 26 CHICAGO–(BUSINESS WIRE)–Byline Bancorp, Inc. (NYSE: BY) announced today that it will issue... Read more.
Gannett to Present at the 26th Annual Needham Growth Conference
MCLEAN, Va.–(BUSINESS WIRE)–Gannett Co., Inc. (“Gannett”, “we”, “our”, or the “Company”) (NYSE: GCI) today announced that it will present... Read more.
Advance Auto Parts Names Elizabeth Dreyer Chief Accounting Officer
RALEIGH, N.C.–(BUSINESS WIRE)–Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts provider in North America that serves both... Read more.
Neurogene Announces Business Update and 2024 Outlook
DSMB clears third pediatric patient for dosing in ongoing NGN-401 Phase 1/2 clinical trial for Rett syndrome; On track to dose third pediatric patient in early 1Q:24... Read more.
SimBioSys® Elevates Leadership Team as It Receives First FDA Clearance for Digital Precision Medicine Platform, TumorSight™
– Seasoned HealthTech Executive Jyoti Palaniappan Appointed as Chief Commercial Officer CHICAGO–(BUSINESS WIRE)–SimBioSys®, a trailblazing TechBio... Read more.
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0%... Read more.
CI Global Asset Management Announces Confirmed Annual Reinvested Distributions for JFT Strategies Fund
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO–(BUSINESS WIRE)–$CIX #CIFinancial—CI... Read more.